Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

医学 伦瓦提尼 索拉非尼 肝细胞癌 内科学 打开标签 肿瘤科 临床试验
作者
Arndt Vogel,Shukui Qin,Masatoshi Kudo,Yun Su,Stacie Hudgens,Tatsuya Yamashita,Jung‐Hwan Yoon,Lætitia Fartoux,Krzysztof Simon,Carlos López,Max W. Sung,Kalgi Mody,Tatsuroh Ohtsuka,Toshiyuki Tamai,L. Michelle Bennett,Genevieve Meier,Valery Breder
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:6 (8): 649-658 被引量:153
标识
DOI:10.1016/s2468-1253(21)00110-2
摘要

Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The aim of this study was to evaluate the effect of treatment with lenvatinib versus sorafenib on HRQOL.REFLECT was a previously published multicentre, randomised, open-label, non-inferiority phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment for unresectable hepatocellular carcinoma. Eligible patients were aged 18 years or older with unresectable hepatocellular carcinoma and one or more measurable target lesion per modified Response Evaluation Criteria in Solid Tumors criteria, Barcelona Clinic Liver Cancer stage B or C categorisation, Child-Pugh class A, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or lower, and adequate organ function. Patients were randomly assigned (1:1) via an interactive voice-web response system; stratification factors for treatment allocation included region; macroscopic portal vein invasion, extrahepatic spread, or both; ECOG performance status; and bodyweight. Patient-reported outcomes (PROs), collected at baseline, on day 1 of each subsequent cycle, and at the end of treatment, were evaluated in post-hoc analyses of secondary and exploratory endpoints in the analysis population, which was the subpopulation of patients with a PRO assessment at baseline. A linear mixed-effects model evaluated change from baseline in PROs, including European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and hepatocellular carcinoma-specific QLQ-HCC18 scales (both secondary endpoints of the REFLECT trial). Time-to-definitive-deterioration analyses were done based on established thresholds for minimum differences for worsening in PROs. Responder analyses explored associations between HRQOL and clinical response. This study is registered with ClinicalTrials.gov, NCT01761266.Of 954 eligible patients randomly assigned to lenvatinib (n=478) or sorafenib (n=476) between March 14, 2013, and July 30, 2015, 931 patients (n=468 for lenvatinib; n=463 for sorafenib) were included in this analysis. Baseline PRO scores reflected impaired HRQOL and functioning and considerable symptom burden relative to full HRQOL. Differences in overall mean change from baseline estimates in most PRO scales generally favoured the lenvatinib over the sorafenib group, although the differences were not nominally statistically or clinically significant. Patients treated with lenvatinib experienced nominally statistically significant delays in definitive, meaningful deterioration on the QLQ-C30 fatigue (hazard ratio [HR] 0·83, 95% CI 0·69-0·99), pain (0·80, 0·66-0·96), and diarrhoea (0·52, 0·42-0·65) domains versus patients treated with sorafenib. Significant differences in time to definitive deterioration were not observed for other QLQ-C30 domains, and there was no difference in time to definitive deterioration on the global health status/QOL score (0·89, 0·73-1·09). For most PRO scales, differences in overall mean change from baseline estimates favoured responders versus non-responders. Across all scales, HRs for time to definitive deterioration were in favour of responders; median time to definitive deterioration for responders exceeded those for non-responders by a range of 4·8 to 14·6 months.HRQOL for patients undergoing treatment for unresectable hepatocellular carcinoma is an important therapeutic consideration. The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with sorafenib to delay functional deterioration in advanced hepatocellular carcinoma.Eisai and Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
易木发布了新的文献求助10
1秒前
丘比特的应助被瀛洲晚风采纳,获得30
2秒前
包容的墨镜关注了科研通微信公众号
3秒前
Jing发布了新的文献求助10
3秒前
英姑的应助被gfhdf采纳,获得10
5秒前
爆米花的应助被gfhdf采纳,获得10
5秒前
传奇3的应助被gfhdf采纳,获得10
5秒前
5秒前
科研通AI6.2的应助被gfhdf采纳,获得10
5秒前
英俊的铭的应助被gfhdf采纳,获得10
5秒前
打打的应助被gfhdf采纳,获得10
6秒前
丘比特的应助被gfhdf采纳,获得10
6秒前
大个的应助被gfhdf采纳,获得10
6秒前
6秒前
被风吹过的路的应助被tomatoGG采纳,获得10
8秒前
8秒前
要天天开心完成签到,获得积分10
9秒前
匡匡完成签到,获得积分10
11秒前
12秒前
初景的应助被一口辰采纳,获得20
12秒前
李佳琪发布了新的文献求助10
12秒前
13秒前
13秒前
14秒前
14秒前
吴佳欣发布了新的文献求助20
14秒前
14秒前
虎鲸_thEt发布了新的文献求助10
14秒前
ZND关注了科研通微信公众号
15秒前
15秒前
16秒前
Akim的应助被gfhdf采纳,获得10
16秒前
传奇3的应助被gfhdf采纳,获得10
17秒前
英姑的应助被gfhdf采纳,获得10
17秒前
爆米花的应助被gfhdf采纳,获得10
17秒前
Hello的应助被gfhdf采纳,获得10
17秒前
乐乐的应助被gfhdf采纳,获得10
17秒前
汉堡包的应助被gfhdf采纳,获得10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593